Venetoclax with CACAG chemotherapy compared with standard 3+7 chemotherapy for acute monocytic leukemia
Compares two treatment approaches in people with acute monocytic leukemia.
Plain-language title generated from the registry record
Registry title: Venetoclax Combined With CACAG Regimen Versus "3+7" Regimen in the Treatment of Acute Monocytic Leukemia
Key facts
- Where
- Beijing, ChinaSee the 3 sites
- Phase
- Phase 2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people aged 14 to 60 with acute monocytic leukemia. It compares two treatments: venetoclax with the CACAG regimen, and the "3+7" regimen.
- Age
- 14 to 60 years
- Sex
- Men and women can join.
- Disease stage
- Acute monocytic leukemia diagnosed by the 2016 WHO classification. Acute promyelocytic leukemia is not included. Daily-activity level (ECOG) 0-3, expected to live at least 4 months.
Main reasons for not taking part
- Pregnancy or breastfeeding
- Active infection
- Liver function: total bilirubin above 2 times the upper limit of normal, or ALT/AST above 2.5 times
- Kidney function: serum creatinine above 1.5 times the upper limit of normal
- Major organ surgery within 6 weeks before joining
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 14 and 60 years old?
Source: NCT07512700, who can take part
Where in China
- Air Force Medical Center, PLABeijing, ChinaTaking people
- Chinese PLA General HospitalBeijing, ChinaTaking people
- PLA Strategic Support Force's Characteristic Medical CenterBeijing, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Chinese PLA General Hospital
- Trial code
- NCT07512700
- Record updated
- 6 April 2026
- Original description
This study is a multicenter, randomized, prospective Phase II clinical trial designed to compare the effectiveness of two treatment approaches for patients with acute monocytic leukemia.Read full original descriptionShow less
Venetoclax Combined With CACAG Regimen Versus "3+7" Regimen in the Treatment of Acute Monocytic Leukemia: A Prospective, Randomized, Controlled Study
This study is a multicenter, randomized, prospective Phase II clinical trial designed to compare the effectiveness of two treatment approaches for patients with acute monocytic leukemia.
Inclusion: Voluntary participation with written informed consent signed by the participant or a legal guardian; willingness to comply with all study procedures; Age 14 to 60 years at screening, no gender restriction; Diagnosis of acute monocytic leukemia according to the 2016 WHO classification, excluding acute promyelocytic leukemia; No history of severe allergic reactions; Liver function: ALT and AST ≤ 2.5 × upper limit of normal (ULN); total bilirubin ≤ 2 × ULN; Renal function: serum creatinine ≤ 1.5 × ULN; No uncontrolled infection or severe psychiatric disorder; ECOG performance status 0-3; life expectancy ≥ 4 months.
Exclusion: Major organ surgery within 6 weeks prior to enrollment; Known hypersensitivity or contraindication to any study drug; Active infection; Psychiatric illness or other condition that prevents informed consent or compliance with study procedures; Any condition deemed unsuitable for the study by the investigator (e.g., poor compliance, substance abuse); Abnormal liver function: total bilirubin > 2× ULN, ALT/AST > 2.5 × ULN; abnormal renal function: serum creatinine > 1.5 × ULN; Pregnancy or lactation; Long-term smoking or alcohol abuse that may interfere with study outcome evaluation.